首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   723篇
  免费   2篇
电工技术   1篇
综合类   2篇
化学工业   11篇
金属工艺   6篇
机械仪表   1篇
无线电   5篇
一般工业技术   9篇
冶金工业   686篇
自动化技术   4篇
  2023年   1篇
  2022年   2篇
  2020年   1篇
  2017年   1篇
  2014年   1篇
  2013年   1篇
  2012年   2篇
  2011年   5篇
  2010年   1篇
  2008年   2篇
  2007年   2篇
  2006年   1篇
  2004年   4篇
  2003年   6篇
  2002年   5篇
  2001年   2篇
  2000年   1篇
  1999年   29篇
  1998年   217篇
  1997年   128篇
  1996年   90篇
  1995年   28篇
  1994年   44篇
  1993年   26篇
  1992年   4篇
  1991年   7篇
  1990年   7篇
  1989年   4篇
  1988年   6篇
  1987年   8篇
  1986年   12篇
  1985年   5篇
  1984年   1篇
  1982年   2篇
  1981年   3篇
  1980年   11篇
  1977年   16篇
  1976年   35篇
  1975年   2篇
  1972年   1篇
  1955年   1篇
排序方式: 共有725条查询结果,搜索用时 31 毫秒
31.
Arginine-vasopressin (AVP) was acylated with various acyl azides (2a-j) in pH 9.1 buffer to give AVP derivatives (11a-j) modified at the tyrosine side chain with a carbohydrate via a spacer arm. Glycoconjugates of AVP modified at the N-terminal amide (12a-e) were also synthesized from AVP and carboxylic acids (3a-e) using dicyclohexylcarbodiimide and 1-hydroxybenzotriazole as coupling agent. Analogues (11a-j) exhibited greater in vivo antidiuretic activity than AVP. AVP and glycoconjugates (12a-e) were stable in rat plasma. On the other hand, glycoconjugates (11a-i) were found to readily convert to AVP according to first order kinetics. Hence, 11a-j are considered to be prodrugs of AVP.  相似文献   
32.
33.
We investigated the effect of two isomers of retinoic acid (RA), all-trans RA and 9-cis RA, on the proliferation of Y79 human retinoblastoma cells. The two isomers inhibited the cell proliferation in a concentration-dependent manner. The IC50 for this inhibition by all-trans RA and 9-cis RA was 1.50 and 0.15 microM, respectively. The inhibitory effect of 9-cis RA on Y79 cell growth was observed within 24 hr, thereafter the cell number was gradually decreased. In contrast, no inhibition by all-trans RA of Y79 cell growth was observed within 24 hr, thereafter the cell number was slightly increased. In these cases, the cell viability at 4 days after the addition of 9-cis RA and all-trans RA was more than 90% and 95%, respectively. These results indicate that the two RA inhibit the proliferation of Y79 human retinoblastoma cells without inducing the cell death and that the effect of 9-cis RA on the inhibition of Y79 cell growth is much greater than that of all-trans RA.  相似文献   
34.
35.
36.
Flame synthesis is one of the most versatile and promising technologies for large-scale production of nanoscale materials. Pyrolysis has recently been shown to be a useful route for the production of single-walled nanotubes, quantum dots and a wide variety of nanostructured ceramic oxides for catalysis and electrochemical applications. An understanding of the mechanisms of nanostructural growth in flames has been hampered by a lack of direct observations of particle growth, owing to high temperatures (2,000 K), rapid kinetics (submillisecond scale), dilute growth conditions (10(-6) volume fraction) and optical emission of synthetic flames. Here we report the first successful in situ study of nanoparticle growth in a flame using synchrotron X-ray scattering. The results indicate that simple growth models, first derived for colloidal synthesis, can be used to facilitate our understanding of flame synthesis. Further, the results indicate the feasibility of studies of nanometre-scale aerosols of toxicological and environmental concern.  相似文献   
37.
38.
39.
40.
Presentation of 11 cases of retroperitoneal sarcoma. Mean time from the beginning of symptoms to diagnosis is 6 months. The primary complementary study is CT. Surgery was performed in all cases, using complete resection in 6 cases, and partial resection in 5. Ten patients relapsed. 9 of which were treated with surgical rescue, in one or more occasions; chemotherapy was added in 6 cases and radiotherapy in 7. Survival at five years is 68%, with a mean follow-up of 66 months.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号